European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 8-14 , January 2008

Statins in stroke prevention: What an internist should know

Received 27 October 2006 ,Revised 14 April 2007 ,Accepted 7 May 2007.

References 

  1. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976;29:1346–1348
  2. Sacco RL, Adams R, Alberts G, et al. Guidelines for stroke prevention of stroke in patients with ischaemic stroke or transient isquemic attack. Stroke. 2006;37:577–617
  3. Castilla-Guerra L, Espino-Montoro A, Fernández-Moreno MC, López-Chozas JM, Jimernez MD. Statins and stroke. Current clinical practice. Stroke. 2006;37:1153
  4. Ovbiagele B, Saver JL, Bang H, et al. Statins treatment and adherence to national colesterol guidelines after ischaemic stroke. Neurology. 2006;66:1164–1170
  5. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13.000 strokes in 450.000 people in 45 prospective cohorts. Lancet. 1995;346:1647–1653
  6. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  7. Byington RP, Davis BR, Plehn JF, et al. for the PPP Investigators. The Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387–392
  8. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002;106:1690–1695
  9. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–228
  10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  11. Amarenco P, Labreuche J, Lavallée PH, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis. Stroke. 2004;35:2902–2909
  12. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. A randomised placebo-control trial. Lancet. 2002;360:7–22
  13. Ovbiagele B, Kidwell Ch S, Saver JL. Expanding indications for statins in cerebral ischemia. Arch Neurol. 2005;62:67–72
  14. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici H, Rudolf AE, et al. High-dose atorvastatin after stroke or transient ischaemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med. 2006;355:549–559
  15. Hankey GJ. Statins after transient ischaemic attack and ischaemic stroke. Lancet Neurol. 2006;5:810–812
  16. Kent DM. Stroke—an equal opportunity for the initiation of statin therapy. N Engl J Med. 2006;355:613–615
  17. Cohen JS, East JE, Elkind MSV, Khan NA, Mascitelli L, Pezzetta F, et al. Statin therapy after stroke or transient ischaemic attack. N Engl J Med. 2006;355:2368–2371
  18. Rutishauser J. The role of statins in clinical medicine. LDL-cholesterol lowering and beyond. Swiss Med Wkly. 2005;136:41–49
  19. Crisby M, Nordin-Fredickssn G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Circulation. 2001;103:926–933
  20. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880–8885
  21. Casani L, Sanchez-Gómez S, Vilahur G, Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thomb Haemost. 2005;94:1035–1041
  22. Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep. 2005;57:561–956
  23. Becker K, Chopp M. Role of statins in the treatment and prevention of stroke. Stroke. 2004;35(suppl 1):2706–2707
  24. Amarenco P, Lavallée P, Touboul PJ. Statins and stroke prevention. Cerebrovasc Dis. 2004;17(suppl 1):81–88
  25. Vivancos-Mora J, Gil-Núñez AC. Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc Dis. 2005;20(suppl 2):53–67
  26. Cook NR, Cohen J, Hekbert PR, Taylor JO, Henneckens CH. Implications for small reduction in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701–709
  27. National Cholesterol Education Program (NCEP) . Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  28. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  29. Sacco RL, Adams R, Alberts G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for stroke prevention of stroke in patients with ischaemic stroke or transient isquemic attack. Stroke. 2006;37:577–617
  30. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell ChD, et al. Primary prevention of ischaemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2006;37:1583–1633
  31. Ross AM, Ganitas TG. Results of new statins trials: should the low-density lipprotein cholesterol treatment guidelines be revised?. Curr Atheroscler Rep. 2005;7:11–16
  32. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MSV. Recurrent stroke and cardiac risks after first ischaemic stroke. The Northern Manhattan Study. Neurology. 2006;66:641–646
  33. Amarenco P, Tonkin AM. Statins for stroke prevention. Disappointment and hope. Circulation. 2004;109(SupplIII):44–49
  34. Chen J, Zhang ZG, Li Y, et al. Statins can induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743–751
  35. Martí-Fabregas J, Gomis M, Arboix A, et al. Favorable outcome of ischaemic stroke in patients pretreated with statins. Stroke. 2004;35:1117–1123
  36. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke. 2005;36:2072–2076
  37. Sanossian N, Saver JL, Liebeskind DS, Kim D, Razinia T, Ovbiagale B. Achieving target cholesterol goals after stroke: is in-hospital statin initiation the key?. Arch Neurol. 2006;63:1081–1083
  38. Yano K, Reed DM, McLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke. 1989;20:1460–1465
  39. Ebrahim S, Sung J, Song YM, Ferrer RL, Lwalor DA, Davey-Smith G. Serum cholesterol, hemorrhagic stroke and myocardial infarction: Korean national heath system prospective cohort study. BMJ. 2006;333:22–27

PII: S0953-6205(07)00245-2

doi: 10.1016/j.ejim.2007.05.010

European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 8-14 , January 2008

Article Tools